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Abstract
Background: Interferon based therapy is used to eradicate the Hepatitis C Virus from the bodies of the infected
individuals. HCV is highly prevalent in Khyber Pakhtunkhwa (KPK) that is why it is important to determine the
response of standard interferon based therapy in Chronic HCV patients of the region.
Study design: A total of 174 patients were selected for interferon based therapy. The patients were selected from
four different regions of KPK. After confirmation of active HCV infection by Real Time PCR, standard interferon with
ribavirn was given to patients for 6 months. After completion of therapy, end of treatment virologic response (ETR)
was calculated.
Results: Out of total 174 patients, 130 (74.71%) showed ETR and 44 (25.28%) did not show ETR. In district Bunir,
out of 52 patients, 36 (69.23%) showed ETR and 16 (30.79%) did not show ETR. In district Mardan, out of the total
74 patients, 66 (89.18%) were negative for HCV RNA and 8 (10.81%) were resistant to therapy. In Peshawar, out of
22, 16 (60%) were negative and 6 (40%) were positive for HCV RNA at the end of 6 months therapy. In the
Federally Administered Tribal Area (FATA), out of 18 only 10 (55.5%) were negative and 8 (44.45%) were positive for
active HCV infection.
Conclusion: It is concluded that the response of antiviral therapy against HCV infection in chronic HCV patients of
KPK province is 74.71%. The high response rate may be due to the prevalence of IFN-responsive HCV genotypes
(2 and 3) in KPK.
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Background
The hepatitis C virus (HCV), a major public health pro-
blem and the leading cause of chronic liver disease has
affected an estimated 180 million people worldwide [1,2].
The HCV genome is single-stranded, positive-sense
RNA, approximately 9600 bp long and encodes a single
polyprotein. HCV infection has reached epidemic pro-
portions and annually more than one million new cases
of infection are reported world wide. It is believed that
HCV infection is more than that of hepatitis B virus
infection (HBV) [3]. Besides this HCV is the leading
cause of liver transplantation and organ shortage is the
major associated problem. The introduction of effective
therapy for the prevention of such life threatening infec-
tion is the ultimate goal. It is especially more important
in underdeveloped countries, where HCV infection rate
is more and most of the patients have financial problems
for its treatment.
Eradication of the virus is the primitive goal of hepatitis
C treatment that is sustained virologic response (SVR)
which is defined as absence of HCV RNA in serum after 6
months of treatment completion and is evidenced by sen-
sitive molecular tests, Polymerase Chain Reaction (PCR).
It has been observed over the past decades that there is
great improvement in the SVR rates when treatment stra-
tegies have been shifted from interferon monotherapy to
combination interferon plus ribavirin [4,5].
Hepatitis C therapy started with a small trial of recom-
binant human interferon Alfa almost 25 years ago [6].
Interferon was selected because of its broad activities
* Correspondence: bashirdr2001@yahoo.com
1Centre for Biotechnology and Microbiology, University of Peshawar,
Peshawar, Khyber Pakhtunkhwa, Pakistan
Full list of author information is available at the end of the article
Ahmad et al. Virology Journal 2012, 9:18
http://www.virologyj.com/content/9/1/18
© 2012 Ahmad et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.against the viruses and it was thought that it might also
be active against still-undiscovered agent of non-A, non-
B hepatitis. No doubt, interferon was found very active
against HCV and resultant effects were decrease in the
level of serum alanin aminotransferase (ALT). So far
HCV was not discovered, the effects of interferon were
not understood but the result of using interferon was the
r e d u c t i o ni nH C VR N Al e v e l ,w h i c hl e dt oas u s t a i n e d
absence of virus in a proportion of patients [7]. Ribavirin
a nucleoside analogue, known to have activity against
several flaviviruses had strong effects in lowering the
level of aminotransferase and histologic characteristics of
the liver but had little effects on serum HCV RNA levels
[8]. Moreover when ribavirin was combined with inter-
feron then it has increased sustained virologic response
rate [9]. Interferon and ribavirin when given in combina-
tion for 48 weeks then sustained virologic response rates
was 40-50% which is two to three times more than
that obtained with interferon alone [8]. Interferon alpha
(IFN-a) along with ribavirin has been widely used as a
standard treatment option for patients with chronic HCV
infection all over the world [10]. Pegylated interferon
with Ribavirin has better response rate as compared to
standard interferon [11].
In Pakistan the general concept is the use of standard
interferon therapy. This is partly due to economic rea-
sons and Pakistan Society of Gastroenterology and GI
Endoscopy also favours the use of SdIF in genotype-3
[12]. Government of Pakistan is also providing only SdIF
via a special Prime Minister’s initiative programme
against hepatitis, thus PgIF is out of reach for the major-
ity of the patients.
Response rates of standard interferon in chronic HCV
patients have never been investigated in KPK. The study
had focused on the efficacy of standard interferon therapy
as administered in the case of chronic HCV patients in
Khyber Pakhtunkhwa province of Pakistan.
Methodology
To evaluate the response of standard interferon combina-
tion therapy against chronic HCV infection, we selected
four different regions of KPK province. The regions were
districts Bunir, Peshawar, Mardan and FATA region.
Through coordination with practioners and lab workers,
samples were collected from the suspected patients. After
initial screening with ICT and Elisa, PCR test was per-
formed for each patient sample according to the instruc-
tions of the manufacturers (Roboscreen, Germany).
Among the confirmed anti-HCV patients, only 174
patients whose PCR was positive, were selected for inter-
feron therapy keeping in mind the exclusive therapy cri-
teria that is, age of the selected personals (18-55 years),
no co-infection associated, ALT level higher than normal,
platelets and Hb levels within the accepted range, and
stage of cirrhosis. We selected 52 patients from Bunir, 22
from Peshawar, 74 patients from Mardan and 18 from
FATA regions.
PCR positive patients were given standard interferon
combination therapy i.e. interferon alpha 2a (3MIU
thrice a week) plus Ribavirin (1000-1200 mg/day) con-
tinuously for 6 months with repeated testing of ALT
level and HCV RNA during and after the interferon
therapy.
After completion of the 6 months long therapy, the
results obtained were as. Out of total 174 patients, 130
(74.71%) were negative for HCV RNA and showing end
of treatment response (ETR) while 44 (25.28%) were
positive for HCV RNA and did not show ETR. In district
Bunir, out of 52 patients who had completed therapy, 36
patients (69.23%) showed ETR and 16 (30.79%) did not
show the ETR. In district Mardan, we found that out of
total 74 patients who had taken 6 months therapy, 66
(89.18%) were negative for HCV RNA and 8 (10.81%)
were resistant to therapy. In Peshawar district, out of 22,
16 (60%) were negative and 6 (40%) were positive while
in FATA, out of 18 only 10 (55.55%) were negative and 8
(44.45%) were positive (Table 1).
Our study revealed that response rate of combination
therapy was comparatively higher in districts Mardan
(89.18%) and Bunir (69.23%) than in districts Peshawar
(60%) and FATA region (55.55%). The percent response
of overall therapy calculated was 74.71% (Figure 1).
Discussion
Hepatitis C Virus infection is spreading rapidly. HCV
prevalence is nearly 200 million people world wide and
every year infects 3-4 million more people [13]. The sero-
prevalence of Hepatitis C virus in different parts of Paki-
stan, reported in the last 5 years, is from 2.2%-13.5%. The
highest seroprevalence of hepatitis C has been reported
from Lahore (13.5%) [14] Jasmshoro (9%) and Mardan
(9%) [15,16].
Pakistan is a developing country and the literacy rate is
also low, due to which lack of information regarding the
pathogenecity, routes of transmission and the proper pro-
cedures of diagnosis and treatment are rarely followed.
Therefore HCV infection has become an economic burden
on the people of Pakistan and especially in KPK.
In this study we determined the End of Treatment
Response (ETR), defined as the absence of HCV RNA at
the end of 6 months IFN therapy, in chronic HCV
patients. The average calculated ETR was 74.71% and
resistance calculated was 25.28%. Different regions of
KPK province had different ETR rates; like ETR was very
high in district Mardan followed by district Bunir and
lower in district Peshawar and FATA regions [Figure 1].
The average response rate of IFN combination therapy
with ribavirin in chronic HCV patients of KPK
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different population groups which may vary regarding
response to IFN based therapy. Instead, the response
rate was similar to other studies conducted internation-
ally [17-19] as well as locally [20,21], when treated with
IFN and ribavirin combination therapy.
In district Mardan prevalence of HCV infection has
been recorded as 9% [16]. The high ETR rate in district
M a r d a nm i g h tb ed u et ot h eh i g hp r e v a l e n c eo fH C V
genotypes 2 and 3 and might be due to high literacy
rate, as by adopting proper procedures for diagnosis and
treatment, the efficacy rate might be increased as com-
pared to those who have no or little knowledge.
In district Bunir HCV prevalence has also been shown
to be 5% [22]. As this district is less developed and is con-
sidered as an economically poor district, through the
prime minister’s control programme for Hepatitis, HCV
patients have been treated and ETR rate was compara-
tively higher than that of Peshawar and FATA regions
[Table 1].
In district Peshawar the response rate was low as
compared to districts Mardan and Bunir. Low response
rate might be attributed to migration of people from
Afghanistan, from FATA and other associated regions
due to the Floods and regional conflicts. Low response
rate in this district may be due to prevalence of resis-
tance types common in other regions.
In FATA regions, the lowest response was found which
again could be attributed to the prevalence of resistant
HCV genotypes that may have resulted due to the influx
of people from the Gulf and Central Asian Countries.
Conclusion
The above discussion shows that antiviral therapy
against HCV infection in chronic HCV patients of KPK
province is 74.71%. The high response rate may be due
to the prevalence of genotypes 2 and 3.
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